Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 10 | 2024 | 1712 | 0.490 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2018 | 499 | 0.490 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2024 | 949 | 0.370 |
Why?
|
| Neuroblastoma | 6 | 2017 | 543 | 0.320 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 188 | 0.310 |
Why?
|
| Gangliosides | 2 | 2024 | 71 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 162 | 0.250 |
Why?
|
| Interleukin-2 | 4 | 2008 | 236 | 0.230 |
Why?
|
| Cell Culture Techniques | 3 | 2014 | 275 | 0.210 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 60 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2016 | 175 | 0.200 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 470 | 0.190 |
Why?
|
| Bone Marrow Cells | 2 | 2014 | 242 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 211 | 0.170 |
Why?
|
| Cancer Vaccines | 3 | 2007 | 188 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 692 | 0.140 |
Why?
|
| Ki-1 Antigen | 1 | 2017 | 31 | 0.130 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 48 | 0.130 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 29 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 144 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 125 | 0.120 |
Why?
|
| CD28 Antigens | 2 | 2017 | 76 | 0.120 |
Why?
|
| Sialoglycoproteins | 2 | 2007 | 43 | 0.110 |
Why?
|
| Lymphokines | 2 | 2007 | 61 | 0.110 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 235 | 0.110 |
Why?
|
| Immunophenotyping | 5 | 2017 | 331 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 306 | 0.110 |
Why?
|
| Immunotherapy | 3 | 2015 | 760 | 0.100 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 150 | 0.090 |
Why?
|
| K562 Cells | 1 | 2012 | 97 | 0.090 |
Why?
|
| Sarcoma | 1 | 2015 | 218 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 353 | 0.090 |
Why?
|
| Killer Cells, Natural | 2 | 2012 | 351 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 511 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 1273 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2013 | 639 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2011 | 510 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 144 | 0.080 |
Why?
|
| Genetic Therapy | 2 | 2011 | 715 | 0.070 |
Why?
|
| Recoverin | 1 | 2008 | 10 | 0.070 |
Why?
|
| Lymphocyte Activation | 4 | 2012 | 634 | 0.070 |
Why?
|
| Lymphoma | 1 | 2011 | 327 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2008 | 501 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2018 | 12845 | 0.070 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2007 | 9 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2008 | 124 | 0.060 |
Why?
|
| Young Adult | 5 | 2024 | 9997 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 851 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 463 | 0.060 |
Why?
|
| Male | 14 | 2024 | 64470 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2005 | 65 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 326 | 0.060 |
Why?
|
| Child | 10 | 2024 | 26105 | 0.060 |
Why?
|
| Female | 14 | 2024 | 70362 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 384 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2024 | 14948 | 0.050 |
Why?
|
| Humans | 19 | 2024 | 130432 | 0.050 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 23 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1216 | 0.050 |
Why?
|
| Adolescent | 8 | 2024 | 20732 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1268 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 225 | 0.050 |
Why?
|
| Retroviridae | 2 | 2016 | 182 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 273 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 84 | 0.050 |
Why?
|
| Chemokines, C | 1 | 2002 | 10 | 0.050 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 254 | 0.050 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2014 | 83 | 0.050 |
Why?
|
| Leukemia | 1 | 2005 | 375 | 0.050 |
Why?
|
| Cryopreservation | 2 | 2013 | 78 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 271 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 288 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2003 | 213 | 0.040 |
Why?
|
| Myeloid Cells | 2 | 2017 | 112 | 0.040 |
Why?
|
| Cytokines | 3 | 2017 | 1344 | 0.040 |
Why?
|
| Recurrence | 2 | 2015 | 1472 | 0.040 |
Why?
|
| Remission Induction | 2 | 2016 | 304 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 175 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 2061 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1239 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 313 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 496 | 0.040 |
Why?
|
| Middle Aged | 5 | 2018 | 28393 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 667 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 77 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2017 | 41 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 120 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 980 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 124 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2014 | 1919 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2008 | 134 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 1800 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 12 | 0.030 |
Why?
|
| Transduction, Genetic | 2 | 2008 | 279 | 0.030 |
Why?
|
| Adult | 4 | 2017 | 31124 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 785 | 0.030 |
Why?
|
| Infant | 3 | 2024 | 13230 | 0.030 |
Why?
|
| Bioreactors | 1 | 2014 | 43 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1610 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 121 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 62 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 815 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 68 | 0.020 |
Why?
|
| 4-1BB Ligand | 1 | 2012 | 11 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 341 | 0.020 |
Why?
|
| Blood Component Removal | 1 | 2012 | 35 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 713 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1071 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2013 | 258 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 275 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 13 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 110 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 22 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2012 | 103 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 3715 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2191 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2011 | 131 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 582 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 766 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 834 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2011 | 197 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 715 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1485 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 20882 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3379 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5035 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2896 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2007 | 161 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 71 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1483 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2558 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 2003 | 34 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 15 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3752 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2002 | 28 | 0.010 |
Why?
|
| Panniculitis | 1 | 2002 | 17 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 111 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5155 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 227 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 425 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 188 | 0.010 |
Why?
|
| Epitopes | 1 | 2003 | 323 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2003 | 348 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 2461 | 0.010 |
Why?
|
| Vaccination | 1 | 2007 | 1050 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2002 | 174 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 975 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 538 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 793 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 4475 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 33844 | 0.010 |
Why?
|